ClinicalTrials.gg
CompletedNCT03668119CheckMate 848Updated Aug 28, 2024Results posted

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

A Phase 2 interventional study of Nivolumab and Ipilimumab in Pan Tumor, sponsored by Bristol-Myers Squibb. Completed at 60 sites in 17 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-08-28.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this study is to demonstrate the clinical activity of nivolumab in combination with ipilimumab in multiple types of tumors based on their Tumor Mutational Burden status.

02

Conditions studied

  • Pan Tumor

Keywords

  • TMB-H
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a , , or unresectable or cytologically confirmed solid malignant tumor with high tumor mutational burden (TMB-H) who are refractory to standard local therapies, or for which no standard treatment is available.
  • Must be able to provide tissue and blood TMB-H testing results
  • Must have for response assessment

Exclusion criteria

Exclusion Criteria:

  • Participants with melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) or hematological as primary site of disease
  • Participants who received prior treatment with an anti-programmed death-1 (), anti-programmed death ligand 1 (anti-PD-L1), anti-programmed death ligand 2 (anti-PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Treatment with any chemotherapy, radiation therapy, biologics for cancer, or therapy within 28 days of first administration of study treatment

Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
212 participants (actual)

Study arms

  • Experimental
    Nivolumab + Ipilimumab Combination

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Nivolumab Monotherapy

    Biological: Nivolumab

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: Yervoy, BMS-734016

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm A

    ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.

    Time frame: From date of randomization up to 42 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm B

    ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.

    Time frame: From date of randomization up to 57 months

  2. Objective Response Rate (ORR) Per Investigator

    ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on investigator assessment. Calculated using Clopper-Pearson method. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.

    Time frame: From date of randomization up to 57 months

  3. Duration of Response (DoR) Per Investigator

    DoR was defined as the time from first confirmed complete or partial response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: CR= Disappearance of all target lesions. PR= ≥ 30% decrease in the sum of diameters of target lesions. PD= ≥ 20% increase in the sum of diameters of target lesions. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable/improved T2/FLAIR; off corticosteroids; stable/improved clinically PR= ≥ 50% decrease in the sum of diameters of all measurable enhancing lesions; no progression of nonmeasurable disease; no new lesions; stable/improved T2/FLAIR; stable/improved clinically. PD= ≥ 25% increase in sum of diameters of enhancing lesions, on stable/increasing doses of corticosteroids; significant increase in T2/FLAIR; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.

    Time frame: From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)

  4. Duration of Response (DoR) Per Blinded Independent Central Review (BICR)

    DoR was defined as the time from first confirmed complete or partial response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: CR= Disappearance of all target lesions. PR= ≥ 30% decrease in the sum of diameters of target lesions. PD= ≥ 20% increase in the sum of diameters of target lesions. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable/improved T2/FLAIR; off corticosteroids; stable/improved clinically PR= ≥ 50% decrease in the sum of diameters of all measurable enhancing lesions; no progression of nonmeasurable disease; no new lesions; stable/improved T2/FLAIR; stable/improved clinically. PD= ≥ 25% increase in sum of diameters of enhancing lesions, on stable/increasing doses of corticosteroids; significant increase in T2/FLAIR; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.

    Time frame: From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)

  5. Time to Objective Response (TTR) Per Investigator

    TTR is defined as the time from randomization date to the date of the first confirmed response (complete response (CR) or partial response (PR)), based on investigator assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.

    Time frame: From date of randomization to date of first confirmed response (CR or PR) (Up to 57 months)

  6. Time to Objective Response (TTR) Per Blinded Independent Central Review (BICR)

    TTR is defined as the time from randomization date to the date of the first confirmed response (complete response (CR) or partial response (PR)), based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.

    Time frame: From date of randomization to date of first confirmed response (CR or PR) (Up to 57 months)

  7. Clinical Benefit Rate (CBR) Per Investigator

    CBR is defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) or stable disease (SD) based on investigator assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm PR= ≥ 30% decrease in the sum of diameters of target lesions SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD RANO Criteria: CR= Disappearance of all enhancing disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions; stable or improved clinically SD= does not qualify for CR, PR, or progression; stable nonenhancing T2/FLAIR lesions

    Time frame: From date of randomization up to 57 months

  8. Clinical Benefit Rate (CBR) Per Blinded Independent Central Review (BICR)

    CBR is defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) or stable disease (SD) per Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm PR= ≥ 30% decrease in the sum of diameters of target lesions SD= does not qualify for PR or progressive disease RANO Criteria: CR= Disappearance of all enhancing disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions; stable or improved clinically SD= does not qualify for CR, PR, or progression; stable nonenhancing T2/FLAIR lesions

    Time frame: From date of randomization up to 57 months

  9. Progression Free Survival (PFS) Per Investigator

    PFS is defined as the time from randomization date to the date of the first documented tumor progression, determined by investigator assessment, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: Progressive Disease (PD)= ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of ≥ 5 mm. RANO Criteria: PD= ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids; significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.

    Time frame: From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)

  10. Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)

    PFS is defined as the time from randomization date to the date of the first documented tumor progression, determined by Blinded Independent Central Review (BICR) assessment, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: Progressive Disease (PD)= ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of ≥ 5 mm. RANO Criteria: PD= ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids; significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.

    Time frame: From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)

  11. Overall Survival (OS)

    OS is defined as the time between the date of randomization and the date of death due to any cause. Participants who did not have a date of death were censored on the last date for which a participant was known to be alive. Calculated using KM method.

    Time frame: From date of randomization to date of death (Up to 57 months)

  12. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with any grade adverse events (AEs), serious adverse events (SAEs), drug-related AEs, and drug-related SAEs by Tumor Mutational Burden- High (TMB-H) status using worst grade per national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) v5 criteria. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. TMB-H = ≥ 10 mutations per megabase bTMB-H and tTMB-H are not mutually exclusive

    Time frame: From first dose to 30 days post last dose (Up to 25 months)

  13. Number of Participants With On-Treatment Laboratory Parameters

    Number of participants with grade 3-4 on-treatment laboratory parameters. Parameters include hematology, chemistry, liver function, and renal function using worst grade per national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) v5 criteria. Grade 3=Severe event Grade 4=Life threatening event TMB-H = ≥ 10 mutations per megabase bTMB-H and tTMB-H are not mutually exclusive

    Time frame: From first dose to 30 days post last dose (Up to 25 months)

07

Results

Posted May 18, 2023

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneArm A: Nivolumab+IpilimumabArm B: Nivolumab
Started13676
Btmb-h started8045
Ttmb-h started8847
Completed13576
Not completed10
Withdrew: Disease progression10
Treatment
Participant flow — Treatment
MilestoneArm A: Nivolumab+IpilimumabArm B: Nivolumab
Started13576
Btmb-h started8347
Ttmb-h started9450
Arm b rollover022
Completed00
Not completed13576
Withdrew: Disease progression7657
Withdrew: Study drug toxicity191
Withdrew: Death30
Withdrew: Adverse event unrelated to study drug43
Withdrew: Withdrawal by subject11
Withdrew: Participant request to discontinue study treatment31
Withdrew: Maximum clinical benefit01
Withdrew: Participants completed treatment2711
Withdrew: Other reasons21

Outcome measures

PrimaryObjective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm A

ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.

Time frame:
From date of randomization up to 42 months
Reported as:
Number · Precentage of participants
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm A
Precentage of participantsArm A: Nivolumab+Ipilimumab
Blood TMB-H (bTMB-H)22.5 (13.9 to 33.2)
Tissue TMB-H (tTMB-H)38.6 (28.4 to 49.6)
SecondaryObjective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm B

ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.

Time frame:
From date of randomization up to 57 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm B
Percentage of participantsArm B: Nivolumab
Blood TMB-H (bTMB-H)15.6 (6.5 to 29.5)
Tissue TMB-H (tTMB-H)29.8 (17.3 to 44.9)
SecondaryObjective Response Rate (ORR) Per Investigator

ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on investigator assessment. Calculated using Clopper-Pearson method. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.

Time frame:
From date of randomization up to 57 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per Investigator
Percentage of participantsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H)25.0 (16.0 to 35.9)13.3 (5.1 to 26.8)
Tissue TMB-H (tTMB-H)44.3 (33.7 to 55.3)23.4 (12.3 to 38.0)
SecondaryDuration of Response (DoR) Per Investigator

DoR was defined as the time from first confirmed complete or partial response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: CR= Disappearance of all target lesions. PR= ≥ 30% decrease in the sum of diameters of target lesions. PD= ≥ 20% increase in the sum of diameters of target lesions. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable/improved T2/FLAIR; off corticosteroids; stable/improved clinically PR= ≥ 50% decrease in the sum of diameters of all measurable enhancing lesions; no progression of nonmeasurable disease; no new lesions; stable/improved T2/FLAIR; stable/improved clinically. PD= ≥ 25% increase in sum of diameters of enhancing lesions, on stable/increasing doses of corticosteroids; significant increase in T2/FLAIR; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.

Time frame:
From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Reported as:
Median · Months
Duration of Response (DoR) Per Investigator
MonthsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H)27.96 (11.20 to NA)NA (11.24 to NA)
Tissue TMB-H (tTMB-H)NA (27.96 to NA)NA (8.05 to NA)
SecondaryDuration of Response (DoR) Per Blinded Independent Central Review (BICR)

DoR was defined as the time from first confirmed complete or partial response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: CR= Disappearance of all target lesions. PR= ≥ 30% decrease in the sum of diameters of target lesions. PD= ≥ 20% increase in the sum of diameters of target lesions. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable/improved T2/FLAIR; off corticosteroids; stable/improved clinically PR= ≥ 50% decrease in the sum of diameters of all measurable enhancing lesions; no progression of nonmeasurable disease; no new lesions; stable/improved T2/FLAIR; stable/improved clinically. PD= ≥ 25% increase in sum of diameters of enhancing lesions, on stable/increasing doses of corticosteroids; significant increase in T2/FLAIR; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.

Time frame:
From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Reported as:
Median · Months
Duration of Response (DoR) Per Blinded Independent Central Review (BICR)
MonthsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H)NA (10.15 to NA)NA (5.52 to NA)
Tissue TMB-H (tTMB-H)NA (33.51 to NA)NA (8.31 to NA)
SecondaryTime to Objective Response (TTR) Per Investigator

TTR is defined as the time from randomization date to the date of the first confirmed response (complete response (CR) or partial response (PR)), based on investigator assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.

Time frame:
From date of randomization to date of first confirmed response (CR or PR) (Up to 57 months)
Reported as:
Mean · Months
Time to Objective Response (TTR) Per Investigator
MonthsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H)3.48 ± 1.174.08 ± 3.40
Tissue TMB-H (tTMB-H)3.56 ± 1.743.75 ± 2.50
SecondaryTime to Objective Response (TTR) Per Blinded Independent Central Review (BICR)

TTR is defined as the time from randomization date to the date of the first confirmed response (complete response (CR) or partial response (PR)), based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.

Time frame:
From date of randomization to date of first confirmed response (CR or PR) (Up to 57 months)
Reported as:
Mean · Months
Time to Objective Response (TTR) Per Blinded Independent Central Review (BICR)
MonthsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H)3.59 ± 1.654.33 ± 2.93
Tissue TMB-H (tTMB-H)4.37 ± 5.103.98 ± 2.47
SecondaryClinical Benefit Rate (CBR) Per Investigator

CBR is defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) or stable disease (SD) based on investigator assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm PR= ≥ 30% decrease in the sum of diameters of target lesions SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD RANO Criteria: CR= Disappearance of all enhancing disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions; stable or improved clinically SD= does not qualify for CR, PR, or progression; stable nonenhancing T2/FLAIR lesions

Time frame:
From date of randomization up to 57 months
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR) Per Investigator
Percentage of participantsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H)42.5 (31.5 to 54.1)40.0 (25.7 to 55.7)
Tissue TMB-H (tTMB-H)63.6 (52.7 to 73.6)46.8 (32.1 to 61.9)
SecondaryClinical Benefit Rate (CBR) Per Blinded Independent Central Review (BICR)

CBR is defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) or stable disease (SD) per Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm PR= ≥ 30% decrease in the sum of diameters of target lesions SD= does not qualify for PR or progressive disease RANO Criteria: CR= Disappearance of all enhancing disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions; stable or improved clinically SD= does not qualify for CR, PR, or progression; stable nonenhancing T2/FLAIR lesions

Time frame:
From date of randomization up to 57 months
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR) Per Blinded Independent Central Review (BICR)
Percentage of participantsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H)32.5 (22.4 to 43.9)28.9 (16.4 to 44.3)
Tissue TMB-H (tTMB-H)53.4 (42.5 to 64.1)38.3 (24.5 to 53.6)
SecondaryProgression Free Survival (PFS) Per Investigator

PFS is defined as the time from randomization date to the date of the first documented tumor progression, determined by investigator assessment, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: Progressive Disease (PD)= ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of ≥ 5 mm. RANO Criteria: PD= ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids; significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.

Time frame:
From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Per Investigator
MonthsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H)2.99 (2.66 to 4.34)3.04 (2.79 to 5.36)
Tissue TMB-H (tTMB-H)8.15 (4.83 to 12.94)3.06 (2.79 to 10.91)
SecondaryProgression Free Survival (PFS) Per Blinded Independent Central Review (BICR)

PFS is defined as the time from randomization date to the date of the first documented tumor progression, determined by Blinded Independent Central Review (BICR) assessment, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: Progressive Disease (PD)= ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of ≥ 5 mm. RANO Criteria: PD= ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids; significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.

Time frame:
From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)
MonthsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H)2.83 (2.33 to 2.99)2.83 (2.60 to 3.25)
Tissue TMB-H (tTMB-H)5.68 (3.19 to 11.60)2.83 (2.69 to 5.72)
SecondaryOverall Survival (OS)

OS is defined as the time between the date of randomization and the date of death due to any cause. Participants who did not have a date of death were censored on the last date for which a participant was known to be alive. Calculated using KM method.

Time frame:
From date of randomization to date of death (Up to 57 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H)8.07 (5.82 to 10.45)11.24 (5.26 to 18.99)
Tissue TMB-H (tTMB-H)16.48 (10.18 to 30.52)14.59 (7.69 to 18.23)
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of participants with any grade adverse events (AEs), serious adverse events (SAEs), drug-related AEs, and drug-related SAEs by Tumor Mutational Burden- High (TMB-H) status using worst grade per national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) v5 criteria. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. TMB-H = ≥ 10 mutations per megabase bTMB-H and tTMB-H are not mutually exclusive

Time frame:
From first dose to 30 days post last dose (Up to 25 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H) AEs8246
Tissue TMB-H (tTMB-H) AEs9350
bTMB-H SAEs5117
tTMB-H SAEs4616
bTMB-H drug-related AEs6429
tTMB-H drug-related AEs7827
bTMB-H drug-related SAEs171
tTMB-H drug-related SAEs162
SecondaryNumber of Participants With On-Treatment Laboratory Parameters

Number of participants with grade 3-4 on-treatment laboratory parameters. Parameters include hematology, chemistry, liver function, and renal function using worst grade per national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) v5 criteria. Grade 3=Severe event Grade 4=Life threatening event TMB-H = ≥ 10 mutations per megabase bTMB-H and tTMB-H are not mutually exclusive

Time frame:
From first dose to 30 days post last dose (Up to 25 months)
Reported as:
Count of participants · Participants
Number of Participants With On-Treatment Laboratory Parameters
ParticipantsArm A: Nivolumab+IpilimumabArm B: Nivolumab
Blood TMB-H (bTMB-H) Hemoglobin grade 363
Tissue TMB-H (tTMB-H) Hemoglobin grade 387
Blood TMB-H (bTMB-H) Platelet Count grade 3-410
Tissue TMB-H (tTMB-H) Platelet Count grade 3-401
Blood TMB-H (bTMB-H) Leukocytes grade 3- 410
Tissue TMB-H (tTMB-H) Leukocytes grade 3- 400
Blood TMB-H (bTMB-H) Leukocytes Absolute grade 3- 421
Tissue TMB-H (tTMB-H) Leukocytes Absolute grade 3- 453
Blood TMB-H (bTMB-H) Absolute Neutrophil grade 3- 411
Tissue TMB-H (tTMB-H) Absolute Neutrophil grade 3- 400
Blood TMB-H (bTMB-H) Alkaline Phosphatase grade 3-421
Tissue TMB-H (tTMB-H) Alkaline Phosphatase grade 3-420
Blood TMB-H (bTMB-H) Aspartate Aminotransferase grade 3-423
Tissue TMB-H (tTMB-H) Aspartate Aminotransferase grade 3-441
Blood TMB-H (bTMB-H) Alanine Aminotransferase grade 3-452
Tissue TMB-H (tTMB-H) Alanine Aminotransferase grade 3-431
Blood TMB-H (bTMB-H) Bilirubin grade 3-432
Tissue TMB-H (tTMB-H) Bilirubin grade 3-431
Blood TMB-H (bTMB-H) Creatinine grade 3-431
Tissue TMB-H (tTMB-H) Creatinine grade 3-430
Blood TMB-H (bTMB-H) Hypernatremia grade 3-400
Tissue TMB-H (tTMB-H) Hypernatremia grade 3-400
Blood TMB-H (bTMB-H) Hyponatremia grade 3-441
Tissue TMB-H (tTMB-H) Hyponatremia grade 3-431
Blood TMB-H (bTMB-H) Hyperkalemia grade 3-420
Tissue TMB-H (tTMB-H) Hyperkalemia grade 3-420
Blood TMB-H (bTMB-H) Hypokalemia grade 3-440
Tissue TMB-H (tTMB-H) Hypokalemia grade 3-431
Blood TMB-H (bTMB-H) Hypercalcemia grade 3-401
Tissue TMB-H (tTMB-H) Hypercalcemia grade 3-420
Blood TMB-H (bTMB-H) Hypocalcemia grade 3-420
Tissue TMB-H (tTMB-H) Hypocalcemia grade 3-401
Blood TMB-H (bTMB-H) Hyperglycemia grade 3-400
Tissue TMB-H (tTMB-H) Hyperglycemia grade 3-400
Blood TMB-H (bTMB-H) Hypoglycemia grade 3-400
Tissue TMB-H (tTMB-H) Hypoglycemia grade 3-400

Adverse events

Collected over SAEs and AEs are assessed from first dose to 100 days post last dose (Up to 27 months). Participants were assessed for all-cause mortality from their first dose to study completion (Up to 57 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Nivolumab+Ipilimumab97/136 (71.3%)90/135 (66.7%)121/135 (89.6%)
Arm B: Nivolumab42/76 (55.3%)39/76 (51.3%)64/76 (84.2%)
Arm B: Nivolumab+Ipilimumab (Rollover)20/22 (90.9%)11/22 (50%)13/22 (59.1%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventArm A: Nivolumab+IpilimumabArm B: NivolumabArm B: Nivolumab+Ipilimumab (Rollover)
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)43/13525/767/22
UrosepsisInfections and infestations2/1350/762/22
ColitisGastrointestinal disorders4/1350/761/22
Gastric perforationGastrointestinal disorders1/1350/761/22
NauseaGastrointestinal disorders1/1350/761/22
MalaiseGeneral disorders0/1350/761/22
PyrexiaGeneral disorders5/1350/761/22
HepatitisHepatobiliary disorders1/1350/761/22
Prostate infectionInfections and infestations0/1350/761/22
Urinary tract infectionInfections and infestations3/1351/761/22
Most frequent other events
Showing 10 of 49
Most frequent other events
EventArm A: Nivolumab+IpilimumabArm B: NivolumabArm B: Nivolumab+Ipilimumab (Rollover)
DiarrhoeaGastrointestinal disorders50/13514/763/22
PruritusSkin and subcutaneous tissue disorders36/13515/768/22
FatigueGeneral disorders41/13517/762/22
AnaemiaBlood and lymphatic system disorders32/13516/763/22
Decreased appetiteMetabolism and nutrition disorders28/1356/762/22
NauseaGastrointestinal disorders19/13515/764/22
RashSkin and subcutaneous tissue disorders25/1357/761/22
Urinary tract infectionInfections and infestations12/1352/764/22
Abdominal painGastrointestinal disorders23/1356/761/22
ConstipationGastrointestinal disorders23/13510/761/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Nivolumab+IpilimumabArm B: NivolumabTotal
Mean60.0 ± 11.757.6 ± 12.159.2 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Nivolumab+IpilimumabArm B: NivolumabTotal
Female7144115
Male653297
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Nivolumab+IpilimumabArm B: NivolumabTotal
Hispanic or Latino13518
Not Hispanic or Latino452065
Unknown or Not Reported7851129
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Nivolumab+IpilimumabArm B: NivolumabTotal
American Indian or Alaska Native000
Asian639
Native Hawaiian or Other Pacific Islander000
Black or African American112
White12460184
More than one race000
Unknown or Not Reported51217
08

Study locations

60 sites
  • John Wayne Cancer Center
    Santa Monica, California 90404, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Local Institution - 0093
    Minneapolis, Minnesota 55404, United States
  • Broome Oncology
    Johnson City, New York 13790, United States
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • Local Institution - 0079
    Portland, Oregon 97239, United States
  • Local Institution - 0095
    Austin, Texas 78731, United States
  • Local Institution - 0094
    Dallas, Texas 75231, United States
  • Local Institution - 0090
    Houston, Texas 77030, United States
  • Texas Oncology - Northeast Texas
    Tyler, Texas 75702, United States
  • Local Institution - 0016
    Ciudad Autonoma Beunos Aires, Buenos Aires 1431, Argentina
  • Local Institution - 0087
    Ciudad Autónoma de Buenos Aires, Buenos Aires 1280, Argentina
  • Local Institution - 0078
    Caba, 1199, Argentina
  • Local Institution - 0015
    Caba, 1426, Argentina
  • Local Institution - 0119
    Cordoba, 5000, Argentina
  • Local Institution - 0118
    St Leonards, New South Wales 2065, Australia
  • Local Institution - 0062
    Sydney, New South Wales 2010, Australia
  • Local Institution - 0117
    Woolloongabba, Queensland 4102, Australia
  • Local Institution - 0112
    Brussels, 1090, Belgium
  • Local Institution - 0113
    Bruxelles, 1200, Belgium
  • Local Institution - 0114
    Leuven, 3000, Belgium
  • Local Institution - 0010
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0060
    Hamilton, Ontario L8V 5C2, Canada
  • Local Institution - 0036
    Montreal, Quebec H2X 3E4, Canada
  • Local Institution - 0088
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0018
    Santiago, Metropolitana 8330024, Chile
  • Local Institution - 0082
    Santiago, Metropolitana 8420383, Chile
  • Local Institution - 0080
    Copenhagen, 2100, Denmark
  • Local Institution - 0081
    Herlev, 2730, Denmark
  • Local Institution - 0072
    Lyon Cedex 08, 69373, France
  • Local Institution - 0075
    Marseille Cedex 9, 13273, France
  • Local Institution - 0073
    Paris Cedex 5, 75248, France
  • Local Institution - 0074
    Toulouse, 31100, France
  • Local Institution - 0085
    Villejuif, 94805, France
  • Local Institution - 0039
    Berlin, 12200, Germany
  • Local Institution - 0001
    Bonn, 53127, Germany
  • Local Institution - 0002
    Dresden, 01307, Germany
  • Local Institution - 0086
    Essen, 45147, Germany
  • Local Institution - 0043
    Wuerzburg, 97080, Germany
  • Local Institution - 0032
    Genova, 16132, Italy
  • IRCCS Istituto Nazionale Tumori Milano
    Milano, 20133, Italy
  • Local Institution - 0029
    Napoli, 80131, Italy
  • Local Institution - 0031
    Siena, 53100, Italy
  • Local Institution - 0116
    Rotterdam, Zuid-Holland 3015 GD, Netherlands
  • Local Institution - 0115
    Amsterdam, 1066 CX, Netherlands
  • Local Institution - 0076
    Warszawa, Mazowieckie 02-781, Poland
  • Local Institution - 0077
    Gdansk, 80-214, Poland
  • Fundacion De Investigacion
    San Juan, 00927, Puerto Rico
  • Local Institution - 0068
    Cluj-Napoca, Cluj 400015, Romania
  • Local Institution - 0069
    Bucuresti, 022328, Romania
  • Local Institution - 0067
    Craiova, 200542, Romania
  • Local Institution - 0070
    Floresti, 407280, Romania
  • Local Institution - 0071
    Timisoara, Timis, 300239, Romania
  • Local Institution - 0065
    Singapore, Central Singapore 168583, Singapore
  • Local Institution - 0066
    Singapore, 117599, Singapore
  • Local Institution - 0084
    Barcelona, 08035, Spain
  • Local Institution - 0083
    Madrid, 28041, Spain
  • Local Institution - 0110
    Pamplona, 31008, Spain
  • Local Institution - 0106
    London, Greater London W12 OHS, United Kingdom
  • Local Institution - 0107
    Preston, PR2 9HT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in May 2022, 42 months.

Results were first posted in May 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2018
First posted
Sep 12, 2018
StartActual
Oct 31, 2018
Primary completionActual
May 3, 2022
CompletionActual
Aug 2, 2023
Results first posted
May 18, 2023
Last update
Aug 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03668119
Responsible party
Sponsor
First posted
Sep 12, 2018
Start date
Oct 31, 2018
Primary completion
May 3, 2022
Completion
Aug 2, 2023
Results posted
May 18, 2023
Last update
Aug 28, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion